Baseline prevalence and incidence and risk factors for new-onset drug induced hearing loss in adults receiving drug-resistant tuberculosis (DR-TB) treatment in Khayelitsha, South Africa

Master Thesis

2013

Permanent link to this Item
http://hdl.handle.net/11427/10625
Files
thesis_hsf_2013_njuguna_c.pdf (1.73 MB)
Authors
Njuguna, Christine Wanjiku
Supervisors
Cox, Helen
Boulle, Andrew
Journal Title
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher

University of Cape Town

Department
Department of Public Health and Family Medicine
Faculty
Faculty of Health Sciences
License
Series
Abstract
Treatment for drug-resistant tuberculosis (DR-TB) is longer and associated with more significant side-effects than drug susceptible TB. Second line injectable therapy using kanamycin, amikacin or capreomycin is associated with irreversible hearing loss. There is a scarcity of literature regarding the frequency of hearing loss as well as associated risk factors, particularly with long term use. This study aimed to determine the incidence and risk factors for hearing loss among patients receiving second line injectable drugs.
Description

Includes bibliographical references.

Keywords
Epidemiology

Reference:

Njuguna, C. 2013. Baseline prevalence and incidence and risk factors for new-onset drug induced hearing loss in adults receiving drug-resistant tuberculosis (DR-TB) treatment in Khayelitsha, South Africa. University of Cape Town.

Collections
Masters